

GARWIN GERSTEIN & FISHER LLP

BRUCE E. GERSTEIN
SCOTT W. FISHER
JOSEPH OPPER
NOAH H. SILVERMAN
KIMBERLY M. HENNINGS
ELENA K. CHAN
JONATHAN M. GERSTEIN
DAN LITVIN

COUNSELORS AT LAW
WALL STREET PLAZA
88 PINE STREET, 10TH FLOOR
NEW YORK, N.Y. 10005
TEL: (212) 398-0055
FAX: (212) 764-6620

SIDNEY L. GARWIN
(1908-1980)
--
ANNA TYDNIUK
AAKRUTI VAKHARIA

October 3, 2019

Via ECF

The Honorable Colleen McMahon
United States District Court
Southern District of New York
500 Pearl Street, Room 2550
New York, New York 10007

RE: *In re Namenda Direct Purchaser Antitrust Litig.*, No. 15-cv-07488-CM-RWL

Dear Judge McMahon:

Enclosed please find a copy of Plaintiffs' revised Phase One and Phase Two exhibit lists, with objections (exhibits A and B respectively), and the Parties' joint Phase One and Phase Two exhibit lists (exhibits C and D respectively). Plaintiffs are also delivering today two copies of Plaintiffs' proposed exhibits and the Parties' proposed joint exhibits.

Please note that between last night and today, Defendants have withdrawn at least some of their objections to Plaintiffs' exhibits that Plaintiffs referenced their letter to the Court dated October 2, 2019 (ECF No. 879).

Respectfully submitted,

/s/ Dan Litvin
Dan Litvin

EXHIBIT A

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0002	FRX-AT-00000218	FRX-AT-00000252	9/1/2009	Settlement Agreement between Forest and Amneal- Execution Copy with Exhibits A-C		Gupta, Kapil Ex. 16; Cremieux, Pierre Ex. 21; Agovino, Eric Ex. 01	
PX-0005	FRX-AT-03633499	FRX-AT-03633531	9/25/2009	Email with Draft Memantine Settlement Agreement		Ryan, Charles Ex. 53; Agovino, Eric Ex. 02	
PX-0006	FRX-AT-04320734	FRX-AT-04320736	1/21/2010	RE: Mylan Meeting tomorrow		Agovino, Eric Ex. 03; Ryan, Charles Ex. 36	
PX-0008	FRX-AT-03500538	FRX-AT-03500542	2/19/2010	Fw: Draft Complaint		Agovino, Eric Ex. 04	
PX-0009	FRX-AT-03500543	FRX-AT-03500564	00/00/0000	Draft - Complaint Mylan v. Forest		Agovino, Eric Ex. 05	
PX-0010	FRX-AT-03629769	FRX-AT-03629770	2/26/2010	Mylan Pleadings		Agovino, Eric Ex. 06	
PX-0012	FRX-AT-04271302	FRX-AT-04271309	3/8/2010	RE: Forest/Privileged and Confidential - Antitrust and Settlement Slides		Agovino, Eric Ex. 08	402; 403
PX-0013	FRX-AT-03512258	FRX-AT-03512258	3/16/2010	Letter from Daniel V. Folt to Judge Sleet re Forest Labs v Cobalt Labs	MSJ Opinion	Agovino, Eric Ex. 09; Silber, Seth Ex. 11	
PX-0015	FRX-AT-03516651	FRX-AT-03516684	3/19/2010	Email FW: Forest Laboratories, Inc. et al. v. Mylan Pharmaceuticals, Inc		Agovino, Eric Ex. 10; Silber, Seth Ex. 12	
PX-0018	FRX-AT-03521494	FRX-AT-03521529	7/21/2010	Email with attached Signature Pages		Agovino, Eric Ex. 13	
PX-0019	FRX-AT-00000428	FRX-AT-00000463	7/21/2010	Settlement Agreement between Forest Labs; Merz and Mylan Pharmaceuticals	MSJ Opinion	Agovino, Eric Ex. 14; Solomon, David Ex. 08; Silber, Seth Ex. 01; Jochum, Patrick Ex. 10; Cremieux, Pierre Ex. 24	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0024	FRX-AT-00000253	FRX-AT-00000273	10/3/2005	Distribution and Supply Agreement (Generic Lexapro) between Forest and Alphapharm	MSJ Opinion	Agovino, Eric Ex. 15; Carnevale, Robert Ex. 13; Mears, Rachel Ex. 04; Solomon, David Ex. 07; Curia, Katrina Ex. 21; Bruno, James Ex. 03	
PX-0030	FRX-AT-00000464	FRX-AT-00000477	7/21/2010	Amendment to the Distribution and Supply Agreement (Generic Lexapro) between Forest Labs, Alphapharm Pty Ltd. And Mylan Pharmaceuticals	MSJ Opinion	Agovino, Eric Ex. 16; Bruno, James Ex. 04	
PX-0036	FRX-AT-00000001	FRX-AT-00000037	11/13/2009	Settlement Agreement between Forest Laboratories, Merz Pharma Gmbh & Co. and Dr. Reddy's Laboratories with attached exhibits A - C		Cremieux, Pierre Ex. 22; Agovino, Eric Ex. 19	
PX-0052	FRX-AT-03655713	FRX-AT-03655716	9/19/2008	Emails re: Proactive Projects and Partner Meetings		Carnevale, Robert Ex. 04	
PX-0068	FRX-AT-04616753	FRX-AT-04616756	7/6/2010	Emails RE: Mylan Lexapro Authorized Generic		Mears, Rachel Ex. 14; Carnevale, Robert Ex. 12	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0080	FRX-AT-04340635	FRX-AT-04340641	3/14/2010	Emails FW: Mylan Term Sheet with attached Forest/Mylan COGS; Lexapro forecast; Lexapro Medicaid Liability; Status of memantine patent litigation		Mears, Rachel Ex. 09; Solomon, David Ex. 10	
PX-0082	FRX-AT-04579626	FRX-AT-04579626	3/16/2010	Letter from Daniel V. Folt to Judge Sleet re Forest Labs v Cobalt Labs	MSJ Opinion	Mears, Rachel Ex. 10; Solomon, David Ex. 13; Green, Philip Ex. 02	
PX-0085	FRX-AT-04610603	FRX-AT-04610606	3/23/2010	Emails RE: Memantine		Mears, Rachel Ex. 11	
PX-0086	FRX-AT-04593099	FRX-AT-04593102	4/13/2010	Emails FW: Lexapro Information		Mears, Rachel Ex. 13	
PX-0087	FRX-AT-04447018	FRX-AT-04447019.0006	10/18/2007	Emails re: Impact of DRA on Authorized Generics with Attached powerpoint	MSJ Opinion	Mears, Rachel Ex. 15	
PX-0104	FRX-AT-04390579	FRX-AT-04390593	11/19/2010	Draft Minutes of a meeting of the board of directors at Cox Hallett Wilkinson Milner House		Ryan, Charles Ex. 17	
PX-0109	FRX-AT-04269110	FRX-AT-04269434	8/24/2009	Emails re: Update on Namenda settlement with attached agreements		Ryan, Charles Ex. 23	
PX-0122	FRX-AT-04321784	FRX-AT-04321786	2/17/2010	Mylan Standstill Agreement with attached Draft Agreement		Ryan, Charles Ex. 37	
PX-0128	FRX-AT-04229756	FRX-AT-04229759	3/23/2010	Emails re: Memantine		Ryan, Charles Ex. 43	

***In Re Namenda Direct Purchaser Antitrust Litigation* , 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0130	FRX-AT-03882414	FRX-AT-03882420	2/11/2010	Presentation of Forest - Mylan Meeting Subject to FRE 408	MSJ Opinion	Ryan, Charles Ex. 50; Solomon, David Ex. 42; Bonelli, Alexandra Ex. 03; Green, Philip Ex. 07; Snyder, Julie Ex. 03; McKelvie, Roderick Ex. 09; Fowdur, Lona Ex. 04	
PX-0137	FRX-AT-04628512	FRX-AT-04628517	2/11/2010	Presentation of Forest - Mylan Meeting Subject to FRE 409		Ryan, Charles Ex. 51	
PX-0138	FRX-AT-03626412	FRX-AT-03626445	8/19/2009	Email with Draft Memantine Settlement Agreement		Ryan, Charles Ex. 52; Silber, Seth Ex. 09	
PX-0140	FRX-AT-04617133	FRX-AT-04617133	00/00/2013	Lexapro Medicaid Liability Q1 CY2012 - Q1 2013		Solomon, David Ex. 11	
PX-0141	n/a	n/a	8/7/2017	Excerpts from Defendants' 8/7/17 Privilege Log		Solomon, David Ex. 12	402; 403; 602; 802
PX-0142	WSGRMEMA_000100	WSGRMEMA_000107	3/17/2010	Email re: Amendment to Distribution and Supply Agreement with attached Amendment Agreement v.2.3.17.doc		Solomon, David Ex. 14; Silber, Seth Ex. 05	
PX-0156	n/a	n/a	2009	Report of the Economic Survey 2009	MSJ Opinion	Solomon, David Ex. 27	802
PX-0157	FRX-AT-03629651	FRX-AT-03629656	2/18/2010	Emails re: Forest/ Mylan Standstill Agreement		Solomon, David Ex. 28; Silber, Seth Ex. 10	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0159	FRX-AT-03629657	FRX-AT-03629683	2/19/2010	Emails re: Draft Complaint with attached complaint		Solomon, David Ex. 29	
PX-0160	FRX-AT-03629684	FRX-AT-03629689	2/19/2010	Emails re: Draft Complaint		Solomon, David Ex. 30	
PX-0161	FRX-AT-03629712	FRX-AT-03629718	2/19/2010	Emails re: Draft Complaint		Solomon, David Ex. 31	
PX-0162	FRX-AT-04628195	FRX-AT-04628196	1/15/2010	Internal draft of Mylan Deal Concept- For settlement purposes only	MSJ Opinion	Solomon, David Ex. 40; Green, Philip Ex. 05; Bruno, James Ex. 17	
PX-0165	FRX-AT-04628198	FRX-AT-04628198	1/20/2010	Mylan Deal Concept- For settlement purposes only	MSJ Opinion	Solomon, David Ex. 41; Green, Philip Ex. 06	
PX-0167	n/a	n/a	5/8/2009	Second Amended Answer and Counterclaims of Defendant Mylan Pharmaceuticals Forest Labs v. Cobalts Labs Case 1:08-cv-00021-LPS Doc 322		Silber, Seth Ex. 03	
PX-0171	FRX-AT-03169424	FRX-AT-03169455	12/17/2007	Notice of Paragraph IV Certification Letter on behalf of Mylan with attached Detailed Statement of Factual and Legal Bases for Mylan's Patent Certification against the '703 Reexamination Certificate		Silber, Seth Ex. 06	
PX-0174	FRX-AT-04406052	FRX-AT-04406054	00/00/2012	Mylan Pharmaceuticals Inc. Forest Laboratories - Escitalopram Qtr 1 2012; Qtr 2 2012; Qtr 3 2012			402; 403

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0175	FRX-AT-04406055	FRX-AT-04406057	1/31/2013	Email re: Escitalopram Royalty Statement Q4CY12 with attached royalty statement and Medicaid expense changes for Q3CY12 ad Q4CY12		Silber, Seth Ex. 14	402; 403
PX-0179	n/a	n/a	5/26/2017	Letter from Brendan Coffman to Dan Litvin re <i>In re Namenda Antitrust Litigation</i> , Civil Action No. 1:15-cv-07488		Curia, Katrina Ex. 22	
PX-0180	MYLMEMA_003582	MYLMEMA_003593	9/28/2010	Mylan Pharmaceuticals Inc. Escitalopram Oxalate Tablets Revision - SNC Board Presentation		Curia, Katrina Ex. 23; Green, Philip Ex. 13	
PX-0181	MYLMEMA_003580	MYLMEMA_003580	00/00/0000	Spreadsheet of Total Cost Anaysis		Curia, Katrina Ex. 24	Illegible; 602; 802
PX-0196	FRX-AT-00000380	FRX-AT-00000416	3/23/2010	Settlement Agreement between Forest Laboratories, Merz Pharma and Orchid		Wilk, Diana Ex. 19	
PX-0206	FRX-AT-04617640	FRX-AT-04617642	1/19/2010	Emails re: Mylan Mtg Next Week with attached Mylan Forecasts, Lexapro Medicaid Liability, and Current Lexapro Cost Analysis	MSJ Opinion	Green, Philip Ex. 03	
PX-0209	FRX-AT-04617115	FRX-AT-04617115	03/00/2016	Lexapro Generic Analysis- Mylan Share of Generic 50%	MSJ Opinion	Green, Philip Ex. 10; Bruno, James Ex. 13	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0211	FRX-AT-04617114	FRX-AT-04617114	03/00/2016	Lexapro Generic Analysis-Mylan Share of Generic 50%		Green, Philip Ex. 11	
PX-0212	FRX-AT-04617550	FRX-AT-04617551	1/13/2010	Emails re: Lexapro Model		Green, Philip Ex. 12	
PX-0218	FRX-AT-03488197	FRX-AT-03488220	10/16/2003	NDA 21-487 Approval Letter		Bray, June Ex. 02	
PX-0219	FRX-AT-04521903 - 14; 53-56; 58-66; 112-113	FRX-AT-04521903 - 14; 53-56; 58-66; 112-113	12/14/2015	Annual Report for Namenda NDA 21-487		Bray, June Ex. 03	
PX-0241	n/a	n/a	6/30/2017	FDA Listing of Authorized Generics		Solomon, David Ex. 05	
PX-0243	MYLMEMA_003597	MYLMEMA_003606	8/18/2010	Mylan Pharmaceuticals Inc. Escitalopram Oxalate Tablets Launch Project Team		Curia, Katrina Ex. 05	
PX-0244	MYLMEMA_003576	MYLMEMA_003578	10/7/2010	October 7, 2010 Meeting Minutes MPI - Forest Escitalopram Kick-off Meeting		Curia, Katrina Ex. 06	
PX-0245	MYLMEMA_003688	MYLMEMA_003692	11/22/2010	Mylan/Forest Escitalopram Tech Transfer Working Group - Core Team Conference Call (Meeting Held November 18, 2010)		Curia, Katrina Ex. 07	
PX-0246	FRX-AT-04408010	FRX-AT-04408041	10/8/2010	Emails Re: Mylan/Forest Escitalopram Tech Transfer Kickoff Meeting Minutes with attachments		Curia, Katrina Ex. 08	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0247	FRX-AT-04605364	FRX-AT-04605385	1/20/2011	Technical/Quality Agreement for Contract Manufacture, Package (Assembly) Testing and Batch Release by and between Forest labs, Mylan Pharmaceuticals and Alphapharm		Curia, Katrina Ex. 11	
PX-0249	MYLMEMA_000332	MYLMEMA_000333	10/16/2007	Letter re: Memantine Hydrochloride Tablets 5 mg and 10 mg U.S. Patent No. 5,061,703 Paragraph IV Certification		Curia, Katrina Ex. 13	
PX-0250	MYLMEMA_000023	MYLMEMA_000026	4/2/2010	Tentative Approval Letter from the FDA to Mylan in reference to 10/16/2007 ANDA		Curia, Katrina Ex. 14	
PX-0251	MYLMEMA_001498	MYLMEMA_001508	10/6/2014	Letter re Minor Amendment - Final Approval Requested (Chemistry, Labeling and Patent Information Provided) (Quality Facility Information Provided)		Curia, Katrina Ex. 15	
PX-0260	AMNEAL0000435	AMNEAL0000447	3/4/2015	Easily Correctable Deficiency - Office of Lifecycle Deug Products - Immediate Release Division-1 Reference # 81846 ANDA # 090041 - Sequence # 0009		Gupta, Kapil Ex. 05	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0261	n/a	n/a	4/10/2015	ANDA Approval Letter for Amenal Pharmaceuticals		Gupta, Kapil Ex. 07	
PX-0262	AMNEAL0000258	AMNEAL0000279	2/9/2015	Minor Amendment - Final Approval Requested ANDA # 090041 - Sequence #0007 with attached Tentative Approval Letter		Gupta, Kapil Ex. 08	
PX-0263	AMNEAL0000402	AMNEAL0000417	2/19/2015	Addendum to Minor Amendment - Final Approval Requested ANDA #090041 - Sequence #0008		Gupta, Kapil Ex. 09	
PX-0266	FRX-AT-03169456	FRX-AT-03169478	12/18/2007	Notice of Paragraph IV Certification Re: Interpharm, Inc.'s Memantine HCl Tablets, 5 and 10 mg; U.S. Patent No. 5,061,703		Gupta, Kapil Ex. 19	
PX-0271	AMNEAL0008438	AMNEAL0008438	3/26/2015	Product Launch / Validation Tracking Sheet		Gupta, Kapil Ex. 24	
PX-0274	DRL (Namenda AT Litig)0001777	DRL (Namenda AT Litig)0001781	4/14/2010	Letter re Application is Approved		McCormick, Jinping Ex. 03	
PX-0275	n/a	n/a	7/13/2015	Press Release re Dr. Reddy's announces the Launch of Memantine Hydrochloride Tablets, USP		McCormick, Jinping Ex. 04	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0278	FRX-AT-03876718	FRX-AT-03876745	1/2/2008	Norice of Paragraph IV Certification re: Dr. Reddy's Laboratories, LTD.'s and Dr. Reddy's Laboratories, Inc.'s 5 MG and 10 MG Memantine Hydrochloride Tablets; US Patent No. 5,061,703		McCormick, Jinping Ex. 17	
PX-0283	DRL (Namenda AT Litig)0000860	DRL (Namenda AT Litig)0000901	12/2/2013	Presentation re US Launches Review		McCormick, Jinping Ex. 27	
PX-0284	DRL (Namenda AT Litig)0000982	DRL (Namenda AT Litig)0001010	3/6/2014	Presentation re FTMR Review		McCormick, Jinping Ex. 28	
PX-0285	DRL (Namenda AT Litig)0000177	DRL (Namenda AT Litig)0000220	8/28/2014	Presentation re NAG: FTMR Monthly Review		McCormick, Jinping Ex. 29	
PX-0286	DRL (Namenda AT Litig)0000452	DRL (Namenda AT Litig)0000490	3/26/2015	Presentation re FTMR Monthly Call		McCormick, Jinping Ex. 30	
PX-0287	DRL (Namenda AT Litig)0000141	DRL (Namenda AT Litig)0000175	5/28/2015	Presentation re FTMR Monthly Review		McCormick, Jinping Ex. 31	
PX-0288	DRL (Namenda AT Litig)0000645	DRL (Namenda AT Litig)0000680	6/25/2015	Presentation re FTMR Monthly Review		McCormick, Jinping Ex. 32	
PX-0298	SUN0007310	SUN0007312	7/14/2015	Email Fw: IMPULSE News - Memantine IR Tablets Launched OTIF		Nadkarni, Bharati Ex. 09	
PX-0321	FRX-AT-00000184	FRX-AT-00000217	11/3/2009	Settlement Agreement between Forest Laboratories, Merz Pharma and Teva Pharmaceuticals		Rabinovic, Lauren Ex. 17	
PX-0349	MNAT_0000001	MNAT_0000301	2/26/2010	Joint Pretrial Order in the Forest Laboratories, Inc., et al. v. Lupin Pharmaceuticals, Inc., et al.		Ryan, Charles Ex. 03; Johnston, George Ex. 03; Hermann, Nathan Ex. 03	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0357	FRX-AT-03389623	FRX-AT-03389633	00/00/1984	Article- Memantine Improves the Cerebral Performance in the Elderly		Farlow, Martin Ex. 16; Ryan, Charles Ex. 05; Schneider, Lon Ex. 11	
PX-0362	FRX-AT-03173429	FRX-AT-03173446	1989	Can Memantine Improve Disturbances of Social Behaviour and Self-Sufficiency Associated with the Organic Brain Syndrome? Therapiewoche 39, No. 14 (1989) 946-952.		Ryan, Charles Ex. 08; Farlow, Martin Ex. 19	
PX-0366	n/a	n/a	7/17/2008	Supplemental Scheduling Order		Ryan, Charles Ex. 11	
PX-0373	n/a	n/a	10/29/1991	United States Patent Number 5,061,703		McKelvie, Roderick Ex. 10; Malinow, Roberto Ex. 09; Hermann, Nathan Ex. 06; Schneider, Lon Ex. 03; Farlow, Martin Ex. 09	
PX-0395	n/a	n/a	00/00/2006	AIPLA Quarterly Journal v.34 2006, <i>Who Wins Patent Infringement Cases</i> .		McKelvie, Roderick Ex. 02	
PX-0396	n/a	n/a	7/00/2002	Generic Drug Entry Prior to Patent Expiration: An FTC Study		McKelvie, Roderick Ex. 03	402; 403; 802
PX-0433	FRX-AT-02713322	FRX-AT-02713331	4/12/2006	Article, "Low Doses of Memantine Disrupt Memory in Adult Rats" The Journal of Neuroscience		Malinow, Roberto Ex. 11; Hermann, Nathan Ex. 17	802

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0434	FRX-AT-02430682	FRX-AT-02430696	00/00/2007	Article, "Memantine Acts as a Cholinergic Stimulant in the Mouse Hippocampus" Journal of Alzheimer's Disease		Malinow, Roberto Ex. 12	802
PX-0435	FRX-AT-02704728	FRX-AT-02704738	10/28/2004	Article, "Memantine Blocks $\alpha 7^*$ Nicotinic Acetylcholine Receptors More Potently than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons" The Journal of Pharmacology and Experimental Therapeutics		Malinow, Roberto Ex. 13	802
PX-0436	FRX-AT-02704739	FRX-AT-02704740	1/13/2005	Article, Comments on "Memantine Blocks $\alpha 7^*$ Nicotinic Acetylcholine Receptors More Potently than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons"		Malinow, Roberto Ex. 14	802
PX-0437	FRX-AT-01892277	FRX-AT-01892303	2/00/2008	Article, "Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain"		Malinow, Roberto Ex. 16	802
PX-0452	n/a	n/a	10/24/1978	United States Patent 4,122,193		Farlow, Martin Ex. 05	
PX-0501	FRX-AT-03930451	FRX-AT-03930455	4/28/2016	Emails re: Saphris Price History Going Back to 2013 with attached WAC and Pricing History		Devlin, Mark Ex. 32	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0525	FRX-AT-00000112	FRX-AT-00000147	10/9/2009	Settlement Agreement between Forest Laboratoies, Merz Pharma GmbH & Co. and Sun with attached exhibits A - C		Cremieux, Pierre Ex. 23	
PX-0578	FRX-AT-03501462	FRX-AT-03501475	4/7/2008	Answer and Counterclaim of Mylan Pharmaceuticals Inc.			
PX-0586	FRX-AT-03598911	FRX-AT-03599104	2/17/2014	Agreement and Plan of Merger by and amoung Actavis PLC, Tango US Holdings., Tango Merger Sub 1 LLC, Tango merger Sub 2 LLC and Forest Laboratories, Inc.			
PX-0619	FRX-AT-04321787	FRX-AT-04321790	2/18/2010	Letter concerning a draft complaint making antitrust allegations regarding Namenda			802
PX-0632	FRX-AT-04406059	FRX-AT-04406059	00/00/2013	Mylan Pharmaceuticals Inc Forest Laboratories- Escitalopram Qtr 2 2013			402; 403
PX-0671	MYLMEMA_000028	MYLMEMA_000030	1/30/2015	Approval Letter for Memantine Hydrochloride Tablets in reference to ANDA submitted on October 16, 2007		Curia, Katrina Ex. 17	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0933	FRX-AT-03600941	FRX-AT-03600948	10/9/2013	Email re: Namenda Transition.ppt with attachments			
PX-1018	FRX-AT-04617561	FRX-AT-04617562	1/13/2010	Email re: tentative approvals for generic lexapro			
PX-1021	FRX-AT-04623445	FRX-AT-04623462	8/11/2011	Email re: Forest Lundbeck amendment with attached draft letter agreement			
PX-1023	FRX-AT-04628199	FRX-AT-04628202	11/18/2011	Inter-Office Memorandum re Letter Agreement between Forest Laboratories Holdings Limited and H. Lundbeck A/S dated October 31, 2011			
PX-1065	n/a	n/a	01/00/2010	FTC Study: Pay-for-Delay: How Drug Company Pay-offs Cost Consumers Billions			402; 403; 802
PX-1090	n/a	n/a	5/13/2015	Generic Competition and Drug Prices			802
PX-1116	n/a	n/a	5/23/2013	Forest Laboratories, Inc., SEC Form 10-K for fiscal year ended March 31, 2013			
PX-1130	FRX-AT-00000038	FRX-AT-00000075	10/15/2009	Settlement Agreement between Forest, Merz and Cobalt Pharma			

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1131	FRX-AT-00000076	FRX-AT-00000111	9/10/2009	Settlement Agreement between Forest, Merz and Workhardt		Venkatesan, Gopalakrishnan Ex. 29	
PX-1132	FRX-AT-00000148	FRX-AT-00000183	9/8/2009	Settlement Agreement between Forest, Merz and Upshire-Smith			
PX-1133	FRX-AT-00000274	FRX-AT-00000308	9/8/2009	Settlement Agreement between Forest, Merz and Apotex			
PX-1134	FRX-AT-00000309	FRX-AT-00000339	12/7/2009	Settlement Agreement between Forest, Merz and Torrent			
PX-1135	FRX-AT-00000340	FRX-AT-00000379	12/11/2009	Settlement Agreement between Forest, Merz and Lupin			
PX-1136	FRX-AT-00000478	FRX-AT-00000514	11/4/2014	Settlement Agreement between Forest, Merz and Aurobindo			
PX-1137	FRX-AT-04611156	FRX-AT-04611191	6/22/2010	FW: Namenda XR Analysts Reports			602; 802
PX-1140	FRX-AT-04623794	FRX-AT-04623819	8/22/2011	FW: Forest Lundbeck amendment			
PX-1157	FRX-AT-04228603	FRX-AT-04228636	11/20/2009	Cameron Weiffenbach 11/20/2009 Expert Report			602; 802

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1166	n/a	n/a	9/18/2009	Namenda IR Stipulation and Order Regarding Proposed Modifications to the Scheduling Order (D.I. 425)			802; 402; 403
PX-1174	FRX-AT-00006522	FRX-AT-00006531	4/14/1989	J. Timothy Greenamyre and Anne B. Young, "Excitatory Amino Acids and Alzheimer's Disease," <i>Neurobiology of Aging</i> (1989) 10:593-602			802
PX-1202	n/a	n/a	2/2/1982	Reisberg, <i>et al.</i> , Diagnosis and Assessment of the Older Patient, Hospital & Community Psychiatry, 104-110 (1982)			802
PX-1203	n/a	n/a	04/00/1982	Maletta et al., Organic Mental Disorders in a Geriatric Outpatient Population, Am. J. Psychiatry 139:4 (April 1982)			802
PX-1205	FRX-AT-03505611	FRX-AT-03505616	07/00/1984	Guy McKhann et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," <i>Neurology</i> , Vol. 34 (July 1984)			802
PX-1210	FRX-AT-00105810	FRX-AT-00105913	00/00/1982	Merz document describing Ambrozi & Danielczyk, demonstrating how a person of ordinary skill in the art would interpret this reference			402; 403; 802

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1212	FRX-AT-03005821	FRX-AT-03005850	6/5/2002	Synopsis Study No. MRZ 90001-9104			602; 802
PX-1214	FRX-AT-03173410	FRX-AT-03173428	10/00/1987	Pilot Study, Akatinol Memantine in Geriatric Patients With Organic Brain Syndrome, English translation of study report, October 1987			402; 403; 602; 802
PX-1216	FRX-AT-02180912	FRX-AT-02180914	00/00/1986	Dr. Roman Gortelmeyer Head of Scientific Information Biometry for Merz, "Biometric evaluation of the results by W. Fleischhacker et al." (1986)			602; 802
PX-1217	FRX-AT-04563782	FRX-AT-04563846	10/7/2009	Mylan's Package Insert			
PX-1232	FRX-AT-02198980	FRX-AT-02198981	00/00/0000	Namenda (memantine HCL) Package Insert			
PX-1352	n/a	n/a	00/00/2016	United States Court of Appeals for the Federal Circuit, <i>Median Time to Disposition of Cases Terminated After Hearing or Submission</i> , (FY 2007–2016)			402; 403; 602; 802; 901
PX-1400	FRX-AT-03511611	FRX-AT-03511613	9/21/2009	Claim Construction Order			
PX-1422	FRX-AT-04617771	FRX-AT-04617775	3/17/2010	Email from Robert Carnevele to David Solomon re: Lexapro Analysis (with attachments)			
PX-1431	FRX-AT-04617528	FRX-AT-04617530	01/07/2010	Email with attachment re: Lexapro Generic Analysis	MSJ Opinion		

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1432	FRX-AT-04617536	FRX-AT-04617538	01/11/2010	Email regarding Lexapro Generic Analysis with attachment			
PX-1434	FRX-AT-04617545	FRX-AT-04617547	01/12/2010	Email re: generic pricing			
PX-1450	FRX-AT-04617764	FRX-AT-04617768	03/16/2010	Email RE: Lexapro Best Price Analysis - Year 2. With attachments: Lexapro Generic Analysis HS - Mylan 50% Share - Wt COGS 01 2010 Years 1 and 2 - 03 2010 Revised.xls; LX Medicaid Liability post LOEv7 (JF 2 year outlook).xls	MSJ Opinion		
PX-1451	FRX-AT-04617769	FRX-AT-04617770	03/16/2010	Email re: Lexapro Medicaid Analysis with attachment			
PX-1452	FRX-AT-04617776	FRX-AT-04617777	03/18/2010	Email re: Lexapro Analysis			
PX-1453	FRX-AT-04617778	FRX-AT-04617780	03/18/2010	Email re: Lexapro Generic Analysis with attachments			
PX-1486	FRX-AT-04617617	FRX-AT-04617617	01/15/2010	Email from Robert Carnevale re: Authorized Generic Model - Updated	MSJ Opinion		
PX-1520	FRX-AT-04406073	FRX-AT-04406073	00/00/2016	Mylan Pharmaceuticals Inc. Forest Laboratories- Escitalopram Qtr 4 2016			402; 403

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1534	FRX-AT-04595004	FRX-AT-04595019	8/20/2014	Email re Mylan Lexapro AG Agreement and attaching Executed amendment to distribution and supply agreement			402; 403
PX-1537	FRX-AT-04134770	FRX-AT-04134771	9/3/2009	Email re: Namenda Financial Analysis with attached analysis		Mark Devlin Ex. 04; SJ; David Solomon Ex. 03	
PX-1539	MYLMEMA_003476	MYLMEMA_003476	00/00/0000	Memantine Spreadsheet			
PX-1540	SUN0007329	SUN0007332	5/5/2010	Ltr correcting approval letter date of May 5, 2010		Nadkarni, Bharati Ex. 07	
PX-1541	SUN0007333	SUN0007337	4/9/2010	Letter re: Tentatively Approved; ANDA amendments		Nadkarni, Bharati Ex. 05	
PX-1542	SUN0010343	SUN0010383	4/12/2010	Minor Amendment - Final Approval Requested Memantine Hydrochloride Tablets, 5 mg and 10 mg (ANDA #90-058) Stipulation and Order Case No. 1:08-cv-00021		Nadkarni, Bharati Ex. 06	

***In Re Namenda Direct Purchaser Antitrust Litigation*, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits**

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1549	AMNEAL0000043	AMNEAL0000044	11/7/2014	Letter from Amneal to the FDA re: ANDA#090041 (Sequence #0004) Memantine Hydrochloride Tablets, 5mg and 10 mg Gratuitous Patent Amendment: Notification of Updated Patent and Exclusivity Statement			
PX-1590	n/a	n/a	1/21/2019	Amneal Website: Amneal at-a-glance			
PX-1595	n/a	n/a	3/31/2004	SEC - Forest Laboratories, Inc. Form 10-K - FYE 2004			
PX-1596	n/a	n/a	3/31/2005	SEC - Forest Laboratories, Inc. Form 10-K - FYE 2005			
PX-1632	n/a	n/a	12/31/2014	United States Securities and Exchange Commission Form 10-K - 2014 for Mylan			
PX-1636	FRX-AT-04406055	FRX-AT-04406057	1/31/2013	Email re: Escitalopram Royalty Statement Q4Y12 with attachments			402; 403
PX-1638	FRX-AT-04193627	FRX-AT-04193631	1/16/2013	Email re: Forest Mental Health News of Interest 1.16.2013			
PX-1641	n/a	n/a	06/00/2017	Proposed 1006- Plaintiffs Purchases 2012-2017			

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 1 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1642	n/a	n/a	06/00/2017	Proposed 1006- Figure 3 Brand and Generic Namenda IR Market Shares			
PX-1643	n/a	n/a	07/00/2017	Proposed 1006- Figure 4 Brand and Generic IR Average Price			
PX-1644	n/a	n/a	07/00/2017	Proposed 1006- Figure 5 Generic Namenda IR Average Price			

EXHIBIT B

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0151	FRX-AT-01684785	FRX-AT-01684793	11/22/2012	Email re: Revised Version with attached Draft of a Letter to Ken Goodman		Solomon, David Ex. 23	402; 403; CE; MIL 16
PX-0232	FRX-AT-03983932	FRX-AT-03983935	1/14/2015	Email re: Update from previous correspondence: information about Namenda (memantine HCI) tablets and Namenda XR with attached Dear Customer letter		Cremieux, Pierre Ex. 05; Snyder, Julie Ex. 08	
PX-0469	FRX-AT-01606209	FRX-AT-01606210	6/13/2012	Email re: XR_Launch Readiness Meeting June 13 2012_version		Devlin, Mark Ex. 06	CE; MIL 16
PX-0470	FRX-AT-03861621	FRX-AT-03861658	9/13/2012	Presentation- Namenda XR Roadmap to Launch		Devlin, Mark Ex. 07	
PX-0476	FRX-AT-01775302	FRX-AT-01775319	6/00/2013	Presentation- Namenda IR to XR Conversion Project - Working Draft		Devlin, Mark Ex. 12	CE; MIL 16
PX-0477	FRX-AT-01593279	FRX-AT-01593283	8/21/2013	FW: Namenda XR Weekly Performance Tracker - WE 8-9-13 with attached spreadsheet		Devlin, Mark Ex. 13	CE; MIL 16
PX-0478	FRX-AT-03860760	FRX-AT-03860760	9/12/2013	Marketing Bulletin re: Conversion of Existing Namenda Patients to Namenda XR		Devlin, Mark Ex. 14	CE; MIL 16
PX-0479	FRX-AT-03724244	FRX-AT-03724249	10/2/2013	Emails re: Updated Namenda model with production forecast with attached forecast		Devlin, Mark Ex. 15	
PX-0480	FRX-AT-01779417	FRX-AT-01779419	10/18/2013	Emails re: Namenda XR Transition Project Team		Devlin, Mark Ex. 16	
PX-0481	FRX-AT-01641155	FRX-AT-01641155	10/00/2013	Namenda IR & XR Conversion Plan October 2013	MSJ Opinion	Devlin, Mark Ex. 17; Cremieux, Pierre Ex. 18	
PX-0483	FRX-AT-01806018	FRX-AT-01806019	10/30/2013	Email re: Namenda conversion with attached Namenda IR and XR - State performance - conversion v1		Devlin, Mark Ex. 18	
PX-0485	FRX-AT-01775242	FRX-AT-01775242	11/17/2014	Namenda XR Incentive Compensation with attached metadata		Devlin, Mark Ex. 20	
PX-0487	FRX-AT-01779498	FRX-AT-01779500	2/14/2014	Forest Laboratories to Discontinue NAMENDA Tablets, Focus of Once-Daily NAMENDA XR		Cremieux, Pierre Ex. 14; Devlin, Mark Ex. 21	

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0490	FRX-AT-01630961	FRX-AT-01630962	2/14/2014	Emails re: XR		Devlin, Mark Ex. 24	
PX-0491	FRX-AT-03793470	FRX-AT-03793513	2/18/2014	Presentation- Namenda Tablets Discontinuation of Sale - Sales Force Training		Devlin, Mark Ex. 25; Cremieux, Pierre Ex. 15	
PX-0493	FRX-AT-03801380	FRX-AT-03801385	2/18/2014	Email re: Important: Namenda IR discontinuation LTC letters in email format attached		Devlin, Mark Ex. 26	
PX-0494	FRX-AT-03734945	FRX-AT-03734945	4/18/2014	Email re: Namenda XR IR Withdrawal Email Timeline with attached updated timeline		Devlin, Mark Ex. 27	
PX-0495	FRX-AT-00970295	FRX-AT-00970297	4/16/2014	Emails re: UHC M&R Namenda IR MD and Member Templates with attached letter		Devlin, Mark Ex. 28	
PX-0496	FRX-AT-03588065	FRX-AT-03588068	4/3/2014	Emails re: 4x4 Week Comparisons for NamendaXR		Devlin, Mark Ex. 29; Cremieux, Pierre Ex. 19	
PX-0498	FRX-AT-04038657	FRX-AT-04038658	4/29/2014	SCC (Senior Commerical Committee) Notes 4-30 with metadata		Devlin, Mark Ex. 30; Cremieux, Pierre Ex. 20	
PX-0506	FRX-AT-01700746	FRX-AT-01700778	5/14/2013	Email re: FY14 Board Presentation with attached FY14 & 5 year Plan Business Review Forest Laboratories, Inc. May 2013 Board of Directors Meeting		Solomon, David Ex. 33	
PX-0507	FRX-AT-04481087	FRX-AT-04481101	05/00/2014	Forest Laboratories Commercial Operations Update Board of Directors May 2014		Solomon, David Ex. 35	
PX-0509	FRX-AT-01670072	FRX-AT-01670081	11/21/2013	Business & Financial Due Diligence		Solomon, David Ex. 37; Cremieux, Pierre Ex. 16	CE; MIL 16
PX-0513	FRX-AT-03670529	FRX-AT-03670532	12/11/2014	Email with press release- Actavis Confirms District Court Ruling to Require Continued Distribution of Namenda IR		Cremieux, Pierre Ex. 01; Fowdur, Lona Ex. 23	

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0515	FRX-AT-03670602	FRX-AT-03670605	12/15/2014	Email with press release- Actavis Will Appeal Injunction Requiring Continued Distribution of Namenda IR		Cremieux, Pierre Ex. 02	
PX-0531	FRX-AT-03684464	FRX-AT-03684466	10/29/2013	Email re: IR/XR Optum PD	MSJ Opinion	Fowdur, Lona Ex. 07	802; CE; MIL 16
PX-0533	FRX-AT-03718466	FRX-AT-03718491	4/23/2013	Email attaching Conversion Rates v2 % of Franchise ppt			602
PX-0559	FRX-AT-01621653	FRX-AT-01621655	2/24/2014	Namenda Royalty Proposal			
PX-0564	FRX-AT-01730731	FRX-AT-01730740	9/14/2013	Email re: Namenda and Carip business reviews with attached Namenda Franchise Business Plan September 2013			CE; MIL 16
PX-0782	FRX-AT-00948025	FRX-AT-00948025	2/15/2014	Email re: Namenda... important!	MSJ Opinion		
PX-0789	FRX-AT-01594102	FRX-AT-01594103	12/8/2013	Email re: Namenda XR Communication	MSJ Opinion		CE; MIL 16
PX-0820	FRX-AT-01610893	FRX-AT-01610896	10/17/2013	Email re: Please review the attached Namenda XR Brand Strategy Marketing Bulletin "Namenda XR-OptumRx (AARP) Medicare Part D' (retail) with attachment	MSJ Opinion		
PX-0822	FRX-AT-01614372	FRX-AT-01614374	2/18/2014	Email re: Namenda Weekly Tracker - 02.07.14			
PX-0826	FRX-AT-01614463	FRX-AT-01614464	00/00/0000	Cell phone message re: Important Information on the Discontinuation of Namenda (memantine HCI) tablets			
PX-0830	FRX-AT-01617439	FRX-AT-01617448	10/2/2013	Email re: Updated Namenda model with production forecast with attachments			
PX-0831	FRX-AT-01627766	FRX-AT-01627791	10/22/2013	Email re: Transcript: FY14 Q2 Earnings Call attaching Q2 2014 Earnings Call	MSJ Opinion		CE; MIL 16
PX-0833	FRX-AT-01630429	FRX-AT-01630453	4/25/2013	Email re: Transcript: FY13 Q4 Earnings Call			
PX-0835	FRX-AT-01639601	FRX-AT-01639601	00/00/0000	Forecast spreadsheet			

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0837	FRX-AT-01642799	FRX-AT-01642802	9/7/2013	Email re: Updated Namenda Model with attached forecast			
PX-0839	FRX-AT-01644132	FRX-AT-01644133	9/23/2013	Email re: Latest Namenda model with attachment			
PX-0841	FRX-AT-01647251	FRX-AT-01647253	10/22/2013	Email re: Namenda XR Managed Care Tracker with attachment	MSJ Opinion		
PX-0849	FRX-AT-01657678	FRX-AT-01657679	8/17/2013	Email re: Namenda XR Overview for Sales.ppt attaching Namenda XR Overview for Sales ppt			
PX-0850	FRX-AT-01670083	FRX-AT-01670083	12/00/2013	Namenda Transition December 2013			CE; MIL 16
PX-0861	FRX-AT-01726785	FRX-AT-01726792	9/8/2014	Declaration of James J. Lah, M.D., Ph.D.			
PX-0883	FRX-AT-01775151	FRX-AT-01775161	9/29/2012	Email re: Examples of follow-on strategy			CE, MIL 16
PX-0884	FRX-AT-01775214	FRX-AT-01775217	5/14/2013	M. Devlin Namenda XR launch MM speech	MSJ Opinion		CE, MIL 16
PX-0887	FRX-AT-01775250	FRX-AT-01775255	9/22/2013	Email string involving William Meury, Tom Nee, & Lei Meng re: "Namenda financials"			CE, MIL 16
PX-0888	FRX-AT-01775264	FRX-AT-01775301	10/00/2013	Namenda IR & XR Conversion Plan			
PX-0889	FRX-AT-01775327	FRX-AT-01775328	2/18/2014	Letter from Forest Labs re: Discontinuation of Namenda (memantine HCl) Tablets			
PX-0890	FRX-AT-01775329	FRX-AT-01775330	02/00/2014	Letter from Forest Labs re: Discontinuation of Namenda (memantine HCl) Tablets			
PX-0893	FRX-AT-01775500	FRX-AT-01775518	1/21/2014	Forest Laboratories Management Discusses Q3 2014 Results - Earnings Call Transcript			CE; MIL 16
PX-0899	FRX-AT-01782799	FRX-AT-01782812	1/7/2014	Transcript of Forest Earnings Call January 7, 2014.	MSJ Opinion		CE; MIL 16

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0900	FRX-AT-01783493	FRX-AT-01783514	11/5/2014	Press Release: Actavis Net Revenue Increases 83% to \$3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to \$3.19			
PX-0901	FRX-AT-01783541	FRX-AT-01783596	2/27/2013	Email attaching "XR Analog Analysis" dated May 7, 2012			
PX-0902	FRX-AT-01783640	FRX-AT-01783651	12/10/2013	Email attaching Namenda Transition Board Final 4a ppt			CE; MIL 16
PX-0906	FRX-AT-01808336	FRX-AT-01808336	3/18/2014	Email string involving Frank Murdolo, William Meury, and Mark Devlin			
PX-0907	FRX-AT-01808455	FRX-AT-01808457	5/15/2014	Email re: Empire Region Managed Care / Namenda Conversion			
PX-0909	FRX-AT-01821687	FRX-AT-01821689	2/14/2014	Email re: Notification of Namenda Tablets Discontinuation - posted on the Drug Shortage Site			
PX-0910	FRX-AT-01827979	FRX-AT-01827981	6/24/2014	Email re: Namenda Condensed Tracker - Week Ending 06/13/14 attaching Namenda Excel Tracker			
PX-0915	FRX-AT-01876733	FRX-AT-01876764	1/17/2014	Email re: Draft Q&A for 3Q Earnings with attachment			
PX-0916	FRX-AT-01893031	FRX-AT-01893041	00/00/0000	Namenda XR Spring POA			
PX-0917	FRX-AT-01893676	FRX-AT-01893678	00/00/0000	Memo re: communications to physicians, caregivers and pharmacies re discontinuation			
PX-0918	FRX-AT-01893766	FRX-AT-01893767	6/26/2014	Email re: observations from CNS workshops at Miami POA			
PX-0925	FRX-AT-03541685	FRX-AT-03541695	5/1/2014	William Kane - CNS Overview POA Managers Meeting			
PX-0926	FRX-AT-03565770	FRX-AT-03565776	2/12/2014	Email re: Namenda Payer Contact Address with attachments Master List Namenda Payer Contact Address and General Non-Contracted Business Partners Letter			

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0927	FRX-AT-03573080	FRX-AT-03573084	1/27/2015	Email re: Namenda XR... The Preferred Brand! With attached January 26, 2015 Namenda XR Update			
PX-0933	FRX-AT-03600941	FRX-AT-03600948	10/9/2013	Email re: Namenda Transition.ppt with attachments			
PX-0938	FRX-AT-03684533	FRX-AT-03684535	10/31/2013	Email re: Forest Request for Member/HCP Outreach Campaign Information with attached UHCMR Outreach Letter Example			602; 802; CE; MIL 16
PX-0940	FRX-AT-03686632	FRX-AT-03686633	2/3/2014	Email re: Namenda XR Conversion by Channel w.e. 01.24.14			CE; MIL 16
PX-0941	FRX-AT-03687698	FRX-AT-03687701	3/4/2014	Email attaching "Copy of MCA Namenda XR 3-4-14.xls"			
PX-0942	FRX-AT-03697143	FRX-AT-03697165	7/24/2013	Email attaching Earnings Transcript Q14 Jul 23 2013			802
PX-0946	FRX-AT-03724325	FRX-AT-03724325	07/00/2015	Forest Forecast document with a Namenda XR entry date of June 2013 and IR LOE date of July 2015			
PX-0948	FRX-AT-03725539	FRX-AT-03725540	10/29/2013	Email attaching Namenda production forecast 10292013 Flex XR LOE.xlsx			
PX-0951	FRX-AT-03735073	FRX-AT-03735091	4/22/2014	Email attaching Namenda Condensed Tracker - Week Ending 04/11/14			
PX-0952	FRX-AT-03735985	FRX-AT-03736013	5/20/2014	Email attaching NamXR v4 5-19 retail			
PX-0955	FRX-AT-03744044	FRX-AT-03744046	1/9/2015	Email attaching NAM24117 Pharmacist Ltr			
PX-0956	FRX-AT-03745356	FRX-AT-03745360	2/3/2015	Email re: Namenda and Namenda XR Updates with attached images			
PX-0957	FRX-AT-03769038	FRX-AT-03769056	10/21/2013	Email re: Namenda Weekly Launch Tracker_WE 10-11-13 with attached Namenda XR Weekly Performance Tracker presentation			

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-0958	FRX-AT-03769057	FRX-AT-03769058	07/00/2015	Forest Forecast document with a Namenda XR entry date of June 2013 and IR LOE date of July 2015			
PX-0964	FRX-AT-03812472	FRX-AT-03812474	1/3/2014	Email re Namenda XR announcement with attached announcement			
PX-0966	FRX-AT-03815533	FRX-AT-03815544	3/2/2014	Email attaching Weekly Portfolio Tracker			
PX-0969	FRX-AT-03852628	FRX-AT-03852730	3/1/2013	Email attaching Namenda Franchise Business Plan			CE; MIL 16
PX-0970	FRX-AT-03859803	FRX-AT-03859904	11/15/2013	Namenda - Optimizing IR-XR Conversion Activating the Caregiver			602; 802
PX-0974	FRX-AT-03864752	FRX-AT-03864815	8/12/2013	Slides: SCC Meeting August 12, 2013 Performance Launch Activities	MSJ Opinion		
PX-0977	FRX-AT-03872025	FRX-AT-03872066	1/2/2014	Namenda Withdrawal Sales Force Training Webex presentation			
PX-0979	FRX-AT-03910305	FRX-AT-03910311	2/19/2015	Email re: Namenda XR - LTC GPO Conversion Data Wk Ending 2/18/15			602; 802
PX-0982	FRX-AT-03982972	FRX-AT-03982975	1/6/2015	Email re: Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of Namenda IR			
PX-0989	FRX-AT-04204937	FRX-AT-04204938	4/27/2012	Email attaching Namenda XR Forecast Assumptions 04272012.xls			602
PX-0991	FRX-AT-04225926	FRX-AT-04225928	11/7/2013	Email re: Maris quoted in istock analyst			602; 802; CE; MIL 16
PX-0998	FRX-AT-04380937	FRX-AT-04380950	2/14/2014	Email re: Namenda XR - Friday (2/14) Notification Plan with attachments			
PX-1018	FRX-AT-04617561	FRX-AT-04617562	1/13/2010	Email re: tentative approvals for generic lexapro			
PX-1093	n/a	n/a	1/6/2015	Bloomberg Transcript, Goldman Sachs CEO Unscripted Health Care Conference			402; 403; 602; 802

In Re Namenda Direct Purchaser Antitrust Litigation, 1:15-cv-07488-CM-RWL
Plaintiffs' Phase 2 Exhibits

PX	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep. Ex. #	Objections
PX-1095	n/a	n/a	5/29/2014	Bloomberg Transcript, Sanford C. Bernstein Strategic Decisions Conference			402; 403; 602; 802, 901; CE; MIL 16
PX-1107	n/a	n/a	7/23/2013	Q1 2014 Forest Laboratories, Inc. Earnings Conference Call	MSJ Opinion		
PX-1521	FRX-AT-01695167	FRX-AT-01695194	4/8/2014	Email String re Important Information on the Discontinuation of Namenda			602; 802; 402; 403; CE; MIL 16
PX-1522	FRX-AT-01592973	FRX-AT-01592978	9/23/2013	Sept. 23, 2013 email copying Meury entitled "Re: Namenda Financials," forecasting "30% conversion from IR to XR in the conventional option."			
PX-1523	FRX-AT-01601391	FRX-AT-01601393	12/2/2013	email and attached presentation entitled "Namenda Disruption Scenarios", at slide 1			
PX-1532	FRX-AT-03749306	FRX-AT-03749308	5/1/2015	Email re: Namenda Email Program Reporting (thru 6/15) with attached Namenda Phase 1 eNewsletter Delivery Reporting Spreadsheet		Lona Fowdur Ex. 24; Pierre Cremieux Ex. 09	
PX-1577	FRX-AT-01630868	FRX-AT-01630888	6/10/2013	Jerry Lynch Speech re: Namenda XR Launch Meeting Dallas, TX			
PX-1709	FRX-AT-01711279	FRX-AT-01711279	00/00/0000	Namenda Sales Spreadsheet			

EXHIBIT C

***In Re Namenda Direct Purchaser Antitrust Litigation* , 1:15-cv-07477-CM-RWL**
Joint Trial Exhibits - Phase 1

Exhibit Number	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep Ex. #
JX-001	FRX-AT-04340638	FRX-AT-04340638	00/00/0000	COGS Summary	MSJ Opinion	Carnevale, Robert Ex. 09A; Bruno, James Ex. 14
JX-002	FRX-AT-04248512	FRX-AT-04248513	3/23/2009	Letter re: U.S. Namenda Enforcement Actions	MSJ Opinion	Solomon, David Ex. 26; Ryan, Charles Ex. 12; Snyder, Julie Ex. 02
JX-003	n/a	n/a	10/29/1991	Document: 5,061,703 Patent		
JX-004	AMNEAL0000043	AMNEAL0000044	11/7/2014	Letter: "RE: ANDA #090041 (Sequence #0004) Memantine Hydrochloride Tablets, 5mg and 10mg Gratuitous Patent Amendment: Notification of Updated Patent and Exclusivity Statement"		
JX-005	DRL (Namenda AT Litig)0001777	DRL (Namenda AT Litig)0001781	4/14/2010	Letter: DRL ANDA 090048 Approval Letter		
JX-006	FRX-AT-00000001	FRX-AT-00000037	11/13/2009	Document: Settlement Agreement with Dr. Reddy's		
JX-007	FRX-AT-00000038	FRX-AT-00000075	10/15/2009	Document: Settlement Agreement with Cobalt		
JX-008	FRX-AT-00000076	FRX-AT-00000111	9/10/2009	Document: Settlement Agreement with Wockhardt		
JX-009	FRX-AT-00000112	FRX-AT-00000147	10/9/2009	Document: Settlement Agreement with Sun		
JX-010	FRX-AT-00000148	FRX-AT-00000183	9/8/2009	Document: Settlement Agreement with Upsher-Smith		
JX-011	FRX-AT-00000184	FRX-AT-00000217	11/3/2009	Document: Settlement Agreement with Teva		
JX-012	FRX-AT-00000218	FRX-AT-00000252	9/1/2009	Document: Settlement Agreement with Amneal		
JX-013	FRX-AT-00000274	FRX-AT-00000308	9/8/2009	Document: Settlement Agreement with Apotex		

In Re Namenda Direct Purchaser Antitrust Litigation , 1:15-cv-07477-CM-RWL
Joint Trial Exhibits - Phase 1

Exhibit Number	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep Ex. #
JX-014	FRX-AT-00000309	FRX-AT-00000339	12/7/2009	Document: Settlement Agreement with Torrent		
JX-015	FRX-AT-00000340	FRX-AT-00000379	12/11/2009	Document: Settlement Agreement with Lupin		
JX-016	FRX-AT-00000380	FRX-AT-00000416	3/23/2010	Document: Settlement Agreement with Orchid		
JX-017	FRX-AT-00000428	FRX-AT-00000463	7/21/2010	Document: Settlement Agreement with Mylan		
JX-018	FRX-AT-00000478	FRX-AT-00000514	11/4/2014	Document: Settlement Agreement with Aurobindo		
JX-019	FRX-AT-04628199	FRX-AT-04628202	11/18/2011	Document: "Letter Agreement w Lundbeck re generic Lexapro 10-31-11.pdf"		
JX-020	MYLMEMA_000028	MYLMEMA_000030	2/2/2015	Letter: Mylan ANDA 079225 Approval Letter		
JX-021	MYLMEMA_000332	MYLMEMA_000333	10/16/2007	Letter: "Re: Memantine Hydrochloride Tablets, 5mg and 10mg U.S. Patent No. 5,061,703 Paragraph IV Certification"		
JX-022	SUN0007310	SUN0007312	7/14/2015	Email: "Fw: IMPULSE News-Memantine IR Tablets Launched OTIF"		
JX-023	n/a	n/a	7/25/2017	Certified File History for U.S. Patent No. 5,061,703		
JX-024	n/a	n/a	10/20/2017	Certified File History for Reexamination of U.S. Patent No. 5,061,703		

EXHIBIT D

In Re Namenda Direct Purchaser Antitrust Litigation , 1:15-cv-07488-CM-RWL
Joint Trial Exhibits - Phase 2

Exhibit Number	Beg Doc	End Doc	Doc Date	Description	Cited In MSJ Opinion	Dep Ex. #
JX-025	n/a	n/a	09/00/2014	Document: Namenda XR Label		
JX-026	FRX-AT-01819478	FRX-AT-01819481	01/00/2015	Namenda Prescribing Information website with pop-up re the Court's order and appeal		